Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $8.00

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price objective cut by Scotiabank from $15.00 to $8.00 in a report published on Thursday, Benzinga reports. They currently have a sector outperform rating on the biotechnology company’s stock. A number of other research firms also recently weighed in on PACB. The Goldman Sachs Group […]

Related Keywords

California ,United States ,Oene Mark Van ,Davidw Meline ,Pacific Biosciences ,Prudential Financial Inc ,Group Plc ,Envestnet Asset Management Inc ,Scotiabank ,California Inc ,Goldman Sachs Group ,Ambassador Advisors ,Barclays ,Free Report ,Get Free Report ,Director David ,Investors Weigh In On Pacific Biosciences ,Asset Management ,General Group Plc ,California Daily ,Pacific Biosciences Of California ,Nasdaq Pacb ,Pacb ,Medical ,69404d10 ,Lower Price Target ,